Shanghai Haohai Biological Technology Beheer

Beheer criteriumcontroles 4/4

De CEO Shanghai Haohai Biological Technology is Jianying Wu, benoemd in Jul2010, heeft een ambtstermijn van 14.33 jaar. bezit rechtstreeks 3.69% van de aandelen van het bedrijf, ter waarde HK$ 515.66M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 9.9 jaar en 11 jaar.

Belangrijke informatie

Jianying Wu

Algemeen directeur

CN¥1.9m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	14.3yrs
Eigendom CEO	3.7%
Management gemiddelde ambtstermijn	9.9yrs
Gemiddelde ambtstermijn bestuur	11yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jianying Wu's beloning veranderd ten opzichte van Shanghai Haohai Biological Technology's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	CN¥430m
Jun 30 2024	n/a	n/a	CN¥446m
Mar 31 2024	n/a	n/a	CN¥432m
Dec 31 2023	CN¥2m	n/a	CN¥416m
Sep 30 2023	n/a	n/a	CN¥346m
Jun 30 2023	n/a	n/a	CN¥315m
Mar 31 2023	n/a	n/a	CN¥226m
Dec 31 2022	CN¥2m	CN¥855k	CN¥180m
Sep 30 2022	n/a	n/a	CN¥203m
Jun 30 2022	n/a	n/a	CN¥192m
Mar 31 2022	n/a	n/a	CN¥272m
Dec 31 2021	CN¥1m	CN¥845k	CN¥352m
Sep 30 2021	n/a	n/a	CN¥428m
Jun 30 2021	n/a	n/a	CN¥434m
Mar 31 2021	n/a	n/a	CN¥370m
Dec 31 2020	CN¥1m	CN¥768k	CN¥230m
Sep 30 2020	n/a	n/a	CN¥232m
Jun 30 2020	n/a	n/a	CN¥216m
Mar 31 2020	n/a	n/a	CN¥279m
Dec 31 2019	CN¥2m	CN¥742k	CN¥371m
Sep 30 2019	n/a	n/a	CN¥353m
Jun 30 2019	n/a	n/a	CN¥386m
Mar 31 2019	n/a	n/a	CN¥375m
Dec 31 2018	CN¥1m	CN¥712k	CN¥415m
Sep 30 2018	n/a	n/a	CN¥411m
Jun 30 2018	n/a	n/a	CN¥408m
Mar 31 2018	n/a	n/a	CN¥390m
Dec 31 2017	CN¥1m	CN¥583k	CN¥372m

Compensatie versus markt: De totale vergoeding ($USD 262.96K ) Jianying } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 487.65K ).

Compensatie versus inkomsten: De vergoeding van Jianying is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jianying Wu (60 yo)

14.3yrs

Tenure

CN¥1,904,800

Compensatie

Dr. Jianying Wu has been General Manager of Shanghai Haohai Biological Technology Co., Ltd. since July 23, 2010 and has been its Executive Director since December 2014. Mr. Wu served as a Director at Shang...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yongtai Hou	Executive Chairman	14.3yrs	CN¥1.89m	3.65% HK$ 510.4m
Jianying Wu	GM & Executive Director	14.3yrs	CN¥1.90m	3.69% HK$ 515.7m
Minjie Tang	CFO & Executive Director	7.9yrs	CN¥1.45m	0.036% HK$ 5.1m
Yiyi Chen	Executive Director	9.9yrs	CN¥1.26m	0.26% HK$ 36.1m
Min Tian	Joint Company Secretary	4.9yrs	CN¥868.70k	0.0044% HK$ 618.2k
Caixia Ren	Deputy General Manager	10.2yrs	CN¥912.50k	0.012% HK$ 1.7m
Ming King Chiu	Joint Company Secretary	10yrs	geen gegevens	geen gegevens

9.9yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 6826 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yongtai Hou	Executive Chairman	14.3yrs	CN¥1.89m	3.65% HK$ 510.4m
Jianying Wu	GM & Executive Director	14.3yrs	CN¥1.90m	3.69% HK$ 515.7m
Minjie Tang	CFO & Executive Director	7.8yrs	CN¥1.45m	0.036% HK$ 5.1m
Yiyi Chen	Executive Director	14.3yrs	CN¥1.26m	0.26% HK$ 36.1m
Hongbo Shen	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens
Jie You	Non Executive Director	14.3yrs	geen gegevens	47.38% HK$ 6.6b
Ming Ping Huang	Non-Executive Director	14.3yrs	CN¥150.00k	1.22% HK$ 169.9m
Yuanzhong Liu	Chairman of the Supervisory Committee	14.3yrs	geen gegevens	1.22% HK$ 169.9m
Lei Zhao	Independent Non-Executive Director	4.4yrs	CN¥150.00k	geen gegevens
Zhi Su	Independent Non-Executive Director	4.4yrs	CN¥150.00k	geen gegevens
Zhihong Jiang	Independent Non-Executive Director	4.4yrs	CN¥150.00k	geen gegevens
Yushe Yang	Independent Non-Executive Director	4.4yrs	CN¥150.00k	geen gegevens

11.0yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 6826 zijn ervaren en ervaren (gemiddelde ambtstermijn van 11 jaar).

Shanghai Haohai Biological Technology Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, May 29, 2024

Shanghai Haohai Biological Technology Co., Ltd. Announces Resignation of Guo Yongqing as Independent Non-Executive Director, Chairman of Audit Committee, Member of Remuneration and Appraisal Committee and Member of Nomination Committee

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 12, 2023

Less than half of directors are independent

Shanghai Haohai Biological Technology Co., Ltd. Announces Retirement of Li Yingqi as Independent Non-Executive Director

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 29, 2022

Recent updates

Third quarter 2024 earnings released: EPS: CN¥2.19 (vs CN¥0.36 in 3Q 2023)

Investor sentiment improves as stock rises 20%

Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Shanghai Haohai Biological Technology Co., Ltd. Approves Interim Dividend for the Six Months Ended 30 June 2024

Upcoming dividend of CN¥0.40 per share

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback for 2,229,405 shares, representing 0.95% for CNY 200 million.

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2024 Results on Aug 17, 2024

Shanghai Haohai Biological Technology Co., Ltd. Announces to Distribute A Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of CN¥1.00 per share

First quarter 2024 earnings released: EPS: CN¥0.58 (vs CN¥0.60 in 1Q 2023)

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, May 29, 2024

New major risk - Revenue and earnings growth

Shanghai Haohai Biological Technology Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released

Now 28% overvalued

Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023

Shanghai Haohai Biological Technology Co., Ltd. Announces Resignation of Guo Yongqing as Independent Non-Executive Director, Chairman of Audit Committee, Member of Remuneration and Appraisal Committee and Member of Nomination Committee

Third quarter 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.32 in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Financial Guidance for the Nine Months Ended 30 September 2023

Investor sentiment improves as stock rises 15%

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback.

Second quarter 2023 earnings released: EPS: CN¥0.73 (vs CN¥0.059 in 2Q 2022)

Shanghai Haohai Biological Technology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Upcoming dividend of HK$0.44 per share at 1.4% yield

Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on August 11, 2023

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 12, 2023

First quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.35 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥1.04 (vs CN¥2.00 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released

Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥0.059 (vs CN¥0.76 in 2Q 2021)

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2022 Results on Aug 26, 2022

Shanghai Haohai Biological Technology Co., Ltd. Provides Financial Guidance for the Six Months Ended 30 June 2022

Upcoming dividend of HK$0.82 per share

Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2021

Investor sentiment improved over the past week

Shanghai Haohai Biological Technology Co., Ltd. Announces Retirement of Li Yingqi as Independent Non-Executive Director

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 29, 2022

Full year 2021 earnings released: EPS: CN¥2.00 (vs CN¥1.30 in FY 2020)

Less than half of directors are independent

Shanghai Haohai Biological Technology Co., Ltd. to Report Q1, 2022 Results on Apr 29, 2022

Shanghai Haohai Biological Technology Co., Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2021

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues miss analyst expectations

Shanghai Haohai Biological Technology Co., Ltd. Provides Group Earnings Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.50 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.76 (vs CN¥0.29 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ending June 30, 2021

Investor sentiment improved over the past week

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) entered into the share purchase agreement to acquire an additional 9% stake in Contamac Holdings Limited from John Alexander McGregor for £5.9 million.

First quarter 2021 earnings released: EPS CN¥0.55 (vs CN¥0.14 loss in 1Q 2020)

Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Earnings Guidance for the Three Months Ending March 31, 2021

Full year 2020 earnings released

Shanghai Haohai Biological Technology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 27, 2021

Investor sentiment deteriorated over the past week

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) signed the share transfer agreement to acquire 38.23% in Ouhua Meike (Tianjin) Medical Technology Co., Ltd. from Welly And Bloom Ltd and Refined Beauty By Beth Ltd for approximately CNY 140 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam